Abstract
Sixty postmenopausal women were placed in three groups - control, sex hormone-treated, and CaCO3-treated - and followed for 2 years. Skeletal mass decreased by 1.18%/year in the control group, 0.15%/year in the hormone group, and 0.22%/year in the CaCO3 group by radiogrammetry; and 2.88%/year in the control group, 0.73%/year in the hormone group, and 1.83%/year in the CaCO3 group by photon absorptiometry. The treatment groups differed significantly from the control group except for photon absorptiometry in the CaCO3 group. Bone accretion and resorption decreased in the treatment groups as measured by calcium tracer kinetics, resorption more so than accretion. The authors conclude that [1] these techniques are sufficiently sensitive to detect age-related bone loss; [2] postmenopausal sex-hormone replacement measurably decreases age-related bone loss by suppressing bone turnover, resorption more than accretion; and [3] calcium supplements produce the same effect but at the dose the authors used were slightly less effective.
| Original language | English |
|---|---|
| Pages (from-to) | 649-655 |
| Number of pages | 7 |
| Journal | Annals of Internal Medicine |
| Volume | 87 |
| Issue number | 6 |
| State | Published - 1977 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
Effect of estrogens and calcium carbonate on bone loss in postmenopausal women. / Recker, Robert R.; Saville, P. D.; Heaney, R. P.
In: Annals of Internal Medicine, Vol. 87, No. 6, 1977, p. 649-655.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of estrogens and calcium carbonate on bone loss in postmenopausal women
AU - Recker, Robert R.
AU - Saville, P. D.
AU - Heaney, R. P.
PY - 1977
Y1 - 1977
N2 - Sixty postmenopausal women were placed in three groups - control, sex hormone-treated, and CaCO3-treated - and followed for 2 years. Skeletal mass decreased by 1.18%/year in the control group, 0.15%/year in the hormone group, and 0.22%/year in the CaCO3 group by radiogrammetry; and 2.88%/year in the control group, 0.73%/year in the hormone group, and 1.83%/year in the CaCO3 group by photon absorptiometry. The treatment groups differed significantly from the control group except for photon absorptiometry in the CaCO3 group. Bone accretion and resorption decreased in the treatment groups as measured by calcium tracer kinetics, resorption more so than accretion. The authors conclude that [1] these techniques are sufficiently sensitive to detect age-related bone loss; [2] postmenopausal sex-hormone replacement measurably decreases age-related bone loss by suppressing bone turnover, resorption more than accretion; and [3] calcium supplements produce the same effect but at the dose the authors used were slightly less effective.
AB - Sixty postmenopausal women were placed in three groups - control, sex hormone-treated, and CaCO3-treated - and followed for 2 years. Skeletal mass decreased by 1.18%/year in the control group, 0.15%/year in the hormone group, and 0.22%/year in the CaCO3 group by radiogrammetry; and 2.88%/year in the control group, 0.73%/year in the hormone group, and 1.83%/year in the CaCO3 group by photon absorptiometry. The treatment groups differed significantly from the control group except for photon absorptiometry in the CaCO3 group. Bone accretion and resorption decreased in the treatment groups as measured by calcium tracer kinetics, resorption more so than accretion. The authors conclude that [1] these techniques are sufficiently sensitive to detect age-related bone loss; [2] postmenopausal sex-hormone replacement measurably decreases age-related bone loss by suppressing bone turnover, resorption more than accretion; and [3] calcium supplements produce the same effect but at the dose the authors used were slightly less effective.
UR - http://www.scopus.com/inward/record.url?scp=0017591368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017591368&partnerID=8YFLogxK
M3 - Article
VL - 87
SP - 649
EP - 655
JO - Annals of Internal Medicine
JF - Annals of Internal Medicine
SN - 0003-4819
IS - 6
ER -